Skip to main content
Assets
Sanofi logo
SAN.PAR
Sanofi
Health Care · Pharmaceuticals

French multinational pharmaceutical company developing vaccines, treatments for diabetes, cardiovascular diseases, oncology, and rare diseases.

HQ: FranceListed: France

Historical AI Opinions

Audit every published iPulse AI forecast batch and immutable historical research document for Sanofi.

Historical AI Opinions

Sanofi S.A. (SAN.PAR) AI OPINIONS & ADVISOR ANALYSIS

Read the selected AI Advisor’s complete report, scenarios and forecast. Select Consensus for its investment thesis and a preview of advisor weights. Eligible access unlocks all 11 advisor reports and comparisons.

Updated on 28 November 2025Deep analysis 28 November 2025

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts
AI ResearcherAdvisor config deprecated

Investment Expert AI

Investment framework Framework

Model rating

Buy

5-Year Return Est.

+89.6%

Includes 4.38% annual net dividend contribution

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in EUR.63.8482.29100.74119.18137.63Nov 2020May 2023Nov 2025May 2028Nov 2030Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in EUR.
Quarterly Events ForecastPrice targets, total returns and complete scenario reasoning

Forecast prices in EUR. Returns are cumulative from the forecast anchor. Swipe horizontally to read every column.

QuarterForecastTotal returnScenario
€92.5+7.7%Not Generated this time
€96.8+12.7%Not Generated this time
€102+19.2%Not Generated this time
€107+25.1%Not Generated this time
€112+30.4%Not Generated this time
€116+35.6%Not Generated this time
€120+39.7%Not Generated this time
€125+45.0%Not Generated this time
€128+49.1%Not Generated this time
€131+53.1%Not Generated this time
ADVISOR CONFIGURATION DEPRECATED

1. Investment Thesis — Base Case

Sanofi presents a compelling 'growth at a reasonable price' thesis. The successful separation of the Consumer Healthcare unit (Opella) streamlines operations, allowing a re-rating as a focused biopharma entity. Dupixent remains the central growth engine, with approval in COPD providing a significant revenue tailwind through 2028. While Zantac litigation is largely resolved, creating a cleaner balance sheet, the market remains cautiously optimistic about the pipeline's ability to offset the eventual Dupixent LOE in the early 2030s. We expect steady earnings growth, moderate multiple expansion, and reliable dividends to drive attractive total returns.

2. Scenarios & Signals

2.1. Bull Case

In the bull case, Sanofi successfully transitions into a pure-play immunology and vaccine powerhouse following the Opella separation. Dupixent sales exceed peak estimates, driven by COPD and pediatric indications, solidifying it as a top global drug with effectively extended exclusivity via formulation patents. The pipeline delivers high-impact blockbusters, particularly Tolebrutinib in multiple sclerosis and next-gen vaccines, silencing R&D productivity critics. Valuation multiples expand from historic discounts to match premium peers like Novartis or AstraZeneca (16x-18x P/E) as litigation risks (Zantac) fully dissipate. Robust cash flow supports aggressive dividend growth and smart bolt-on acquisitions.

2.2. Bear Case

The bear case envisions Dupixent growth plateauing earlier than expected due to intensifying competition from novel biologics and biosimilar entry preparations. Pipeline execution falters, with key late-stage assets in immunology failing to meet primary endpoints or facing regulatory delays. The US Inflation Reduction Act (IRA) aggressively targets Sanofi's top-selling drugs earlier than anticipated, compressing margins. The Opella separation fails to unlock significant shareholder value, and capital allocation errors erode trust. The stock remains range-bound or declines as investors price in the looming 2031 patent cliff without a proven replacement engine.

4. References & Context

Search behavior, retained evidence, supplied context, and response token details.
Prompt Tokens: 2,379Thinking Tokens: 869Response Tokens: 7,164Total Tokens: 10,412
Researcher modeSearch enabled · not used

This run was configured as Researcher, but no external search activity was recorded. The model proceeded from the supplied context as sufficient, effectively following a Thinker-style workflow.

Context supplied to the model

Public-safe inputs retained with this immutable forecast publication.

  1. 01

    Market data

    Input Prompt Market Equity Balanced System Instruction Driven Equity H5y S6m Brief Invest Thesis Ts Num Rsk Drv Var1

  2. 02

    Global context in this run

    Not used

  3. 03

    Fundamental data in this run

    Not used

  4. 04

    Forecast output requested

    Output Json Equity H5y S6m Brief Invest Thesis Ts Num Rsk Drv Var1

Original published forecast

Inspect the original revision and sealed receipt when a public record is available. Integrity verification is separate from forecast accuracy.

Research datasets created by iPulse AI and published by Future Edge Group FZE. Use is subject to the iPulse AI Terms of Service and applicable source rights.